Table 3 The relation of poor clinical and pathological response to the clinico-pathological variables.
| Â | Poor clinical Response | p value | Poor pathological Response | p value |
|---|---|---|---|---|
Tumour size | Â | Â | Â | Â |
   <2.5 cm | 1/29(3.4%) |  | 5/45(11%) |  |
   >2.5 cm | 28/29(96.5%) | 0.052 | 40/45(88.8%) | 0.001 |
Tumour Histology | Â | Â | Â | Â |
   Ductal | 26/29(89.6%) | 0.216 | 40/45(74%) | 0.187 |
   Lobular | 1/29(3.4%) |  | 2/45(3.7%) |  |
   Mixed | 2/29(6.8%) |  | 3/45(5.5%) |  |
Tumour stage | Â | Â | Â | Â |
   II | 2/29(6.8%) |  | 8/45(17.7%) | 0.26 |
   III | 24/29(82.7%) | 0.014 | 37/45(82.2%) | 0.26 |
   IV | 3/29(10.3%) |  | Non |  |
Her2/neu positive | 8/29(27.5%) | 0.410 | 8/45(17.7%) | 0.666 |
ER positive | 18/29(62.1%) | 0.396 | 32/45(91.4) | 0.052 |
LVI | 13/29(44.8%) | 0.141 | 23/45(51.1%) | 0.034 |
CA 15-3 before PC | 13/29(50%) | 0.013 | 17/45(37.7%) | 0.044 |
CA 15-3 after PC | 14/29(46.2%) | 0.012 | 16/45(35.5%) | 0.045 |